share_log

Trinity Biotech | 6-K: Report of foreign private issuer (related to financial reporting)

Trinity Biotech | 6-K: Report of foreign private issuer (related to financial reporting)

Trinity Biotech | 6-K：外国发行人报告（业绩相关）
美股SEC公告 ·  2024/09/05 10:57

Moomoo AI 已提取核心信息

Trinity Biotech reported a net loss of $24.0M for 2023, with revenues declining 9.1% to $56.8M. The decrease was mainly due to lower PCR Viral Transport Media sales, reduced laboratory services revenue, and lower haemoglobins revenues. The company recorded impairment charges of $11.1M primarily related to Immco Diagnostics.In January 2024, Trinity acquired Waveform Technologies' CGM assets for $12.5M in cash and 1.8M ADSs, plus contingent consideration up to $20M. The company also secured an amended credit agreement with Perceptive providing $22M additional funding, with $12.5M used for the Waveform acquisition and $9.5M for CGM development.The company announced a comprehensive transformation plan targeting operational efficiency through manufacturing consolidation, cost reductions, and business support function centralization. In April 2023, Trinity divested its Fitzgerald Industries business for approximately $30M, resulting in a $12.7M gain.
Trinity Biotech reported a net loss of $24.0M for 2023, with revenues declining 9.1% to $56.8M. The decrease was mainly due to lower PCR Viral Transport Media sales, reduced laboratory services revenue, and lower haemoglobins revenues. The company recorded impairment charges of $11.1M primarily related to Immco Diagnostics.In January 2024, Trinity acquired Waveform Technologies' CGM assets for $12.5M in cash and 1.8M ADSs, plus contingent consideration up to $20M. The company also secured an amended credit agreement with Perceptive providing $22M additional funding, with $12.5M used for the Waveform acquisition and $9.5M for CGM development.The company announced a comprehensive transformation plan targeting operational efficiency through manufacturing consolidation, cost reductions, and business support function centralization. In April 2023, Trinity divested its Fitzgerald Industries business for approximately $30M, resulting in a $12.7M gain.
Trinity Biotech在2023年报告净亏损2400万美元，营业收入下降9.1%，至5680万美元。下降主要是由于PCR病毒运输介质销售减少、实验室服务收入减少和血红蛋白收入下降。公司确认针对Immco Diagnostics的减值损失为1110万美元。在2024年1月，Trinity以1250万美元现金和180万ADS收购Waveform Technologies的CGm资产，并附带最高可达2000万美元的或有对价。公司还与Perceptive达成修订的信用协议，提供2200万美元的额外融资，其中1250万美元用于Waveform收购，950万美元用于CGm开发。公司宣布了一项全面的转型计划，旨在通过制造业-半导体整合、成本削减和业务支持功能集中化来提高运营效率。2023年4月，Trinity以约3000万美元出售了Fitzgerald Industries业务，获得了1270万美元的收益。
Trinity Biotech在2023年报告净亏损2400万美元，营业收入下降9.1%，至5680万美元。下降主要是由于PCR病毒运输介质销售减少、实验室服务收入减少和血红蛋白收入下降。公司确认针对Immco Diagnostics的减值损失为1110万美元。在2024年1月，Trinity以1250万美元现金和180万ADS收购Waveform Technologies的CGm资产，并附带最高可达2000万美元的或有对价。公司还与Perceptive达成修订的信用协议，提供2200万美元的额外融资，其中1250万美元用于Waveform收购，950万美元用于CGm开发。公司宣布了一项全面的转型计划，旨在通过制造业-半导体整合、成本削减和业务支持功能集中化来提高运营效率。2023年4月，Trinity以约3000万美元出售了Fitzgerald Industries业务，获得了1270万美元的收益。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Pacific Biosciences of California
    PACB
    -- 1.850
    Avita Medical
    RCEL
    -- 10.570
    PAVmed
    PAVM
    -- 0.7900
    古特拉
    CUTR
    -- 0.481
    Lifeward
    LFWD
    -- 2.185
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    美联储暂停降息，你如何调整持仓？
    美联储宣布基准利率维持在4.25%—4.50%不变，符合市场预期。你会如何配置资产？ 展开
    联邦公开市场委员会新闻发布会，2025年1月29日